ClinicalTrials.Veeva

Menu

Non-invasive Vagal Stimulation for Frequent Premature Ventricular Complexes ((NoVa-PVC))

Northwell Health logo

Northwell Health

Status

Enrolling

Conditions

Premature Ventricular Contraction

Treatments

Device: Sham device
Device: Parasym device

Study type

Interventional

Funder types

Other

Identifiers

NCT05341544
22-0076

Details and patient eligibility

About

A prospective sham-controlled randomized clinical trial to assess the effect of low-level tragus stimulation (LLTS) in patients with frequent premature ventricular complexes (PVCs)

Full description

This is a two-center, prospective, cross-over, sham-controlled, double-blinded, randomized clinical trial. All the patients will receive a cardiac event monitor at baseline for 28 days, the patient will switch the ePatch after 14 days . Patients will be allocated to either LLTS first and then sham-stimulation, or sham-stimulation first and then LLTS. Each treatment period (sham-stimulation and LLTS) will last 10 days. The Parasym device will be used, and the patients will receive LLTS or sham-stimulation for 1 hour daily. The wash-out period between the two treatments will last 8 days. Patients will be continually monitored via event monitor for 28 days in duration.

Enrollment

60 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adults (>18 years old) but < 80 years of age
  • Symptomatic PVCs or asymptomatic PVCs with a burden > 5%
  • Intolerant to or unwilling to take beta blockers and nondihydropyridine calcium channel blockers or beta blockers and nondihydropyridine calcium channel blockers have proved ineffective

Exclusion criteria

  • Ischemic cardiomyopathy with LVEF < 40%
  • Severe heart failure (New York Heart Association Class III, or IV) or valve disease
  • Sustained ventricular tachycardia
  • Structural heart disease or myocardial scar
  • Pregnancy or nursing
  • Patients with known thyroid issues, on renal dialysis.
  • Patients with prolonged first-degree block, high degree AV block (2nd or 3rd degree), bivascular block and documented sick sinus syndrome
  • Hypotension due to autonomic dysfunction
  • Patients with cardiac implantable electronic device (ICD or PPM) , hearing aid implants or any implanted metallic or electronic device
  • Patients who have had prior cervical vagotomy
  • Patients with skin on the tragus that is broken or cracked
  • Patients with a history of baseline cardiac disease or atherosclerotic cardiovascular disease, including congestive heart failure (CHF), known severe coronary artery disease or recent myocardial infarction (within 5 years) and patients diagnosed with narrowing of the arteries (carotid atherosclerosis)

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Quadruple Blind

60 participants in 2 patient groups

Active
Experimental group
Description:
Patients will receive 1 hour of active low level tragus stimulation daily for 10 days.
Treatment:
Device: Parasym device
Sham
Sham Comparator group
Description:
Patients will receive 1 hour of sham low level tragus stimulation daily for 10 days.
Treatment:
Device: Sham device

Trial contacts and locations

2

Loading...

Central trial contact

Kristie Coleman, RN

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems